Quizartinib - Daiichi Sankyo Company

Drug Profile

Quizartinib - Daiichi Sankyo Company

Alternative Names: AC-010220; AC-220; ASP-2689

Latest Information Update: 12 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ambit Biosciences Corporation
  • Developer Cancer Research UK; Cardiff University; Daiichi Sankyo Company; University of Hong Kong; University of Texas M. D. Anderson Cancer Center
  • Class 3-ring heterocyclic compounds; Antineoplastics; Benzothiazoles; Imidazoles; Isoxazoles; Morpholines; Phenylurea compounds; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Macrophage colony stimulating factor receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Acute myeloid leukaemia
  • Phase II/III Myelodysplastic syndromes
  • Discontinued Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 05 Nov 2018 Preregistration for Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater) in Italy (PO)
  • 05 Nov 2018 The EMA accepted the MAA application and validated for review and granted accelerated assessment for Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater)
  • 01 Nov 2018 Quizartinib receives accelerated assessment status in Japan for Acute myeloid leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top